Submissions for variant NM_000094.4(COL7A1):c.3940_3963del (p.Gly1314_Ala1321del)

dbSNP: rs1451652011

Total submissions: 1

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV003879928	SCV004684553	pathogenic	not provided	2024-01-09	criteria provided, single submitter	clinical testing	This variant, c.3940_3963del, results in the deletion of 8 amino acid(s) of the COL7A1 protein (p.Gly1314_Ala1321del), but otherwise preserves the integrity of the reading frame. This variant is present in population databases (no rsID available, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with COL7A1-related conditions. This variant disrupts the triple helix domain of COL7A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236), and variants at these glycine residues in COL7A1 are more frequently observed in individuals with disease than in the general population (PMID: 22058051). However, the clinical significance of this observation remains uncertain since only a limited number of affected individuals have been described to date. This variant disrupts a region of the COL7A1 protein in which other variant(s) (p.Gly1314Arg) have been determined to be pathogenic (PMID: 19681861; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.